Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

BACKGROUND: The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide–dexamethasone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM) following one to three p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hematol Oncol
Main Authors: Hou, Jian, Jin, Jie, Xu, Yan, Wu, Depei, Ke, Xiaoyan, Zhou, Daobin, Lu, Jin, Du, Xin, Chen, Xiequn, Li, Junmin, Liu, Jing, Gupta, Neeraj, Hanley, Michael J., Li, Hongmei, Hua, Zhaowei, Wang, Bingxia, Zhang, Xiaoquan, Wang, Hui, van de Velde, Helgi, Richardson, Paul G., Moreau, Philippe
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5500972/
https://ncbi.nlm.nih.gov/pubmed/28683766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0501-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados